BIOGEN INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
BIOGEN INC. (BIIB) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of -2.30% for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-15.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2023-02-15
- BIOGEN INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for the quarter ending 2010-09-30 was 21.60%, a 2300.00% increase year-over-year.
- BIOGEN INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for the quarter ending 2010-06-30 was 0.80%, a 42.86% decline year-over-year.
- BIOGEN INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for the quarter ending 2010-03-31 was 0.80%.
- BIOGEN INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for the quarter ending 2009-09-30 was 0.90%.
- BIOGEN INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2022 was -2.30%, a 143.40% decline from fiscal 2021.
- BIOGEN INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2021 was 5.30%, a 5200.00% increase from fiscal 2020.
- BIOGEN INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2020 was 0.10%.
- BIOGEN INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2019 was 0.00%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 3 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 6 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 9 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|---|---|---|
| 2022-12-31 | -2.30% 10-K · filed 2023-02-15 | |||
| 2021-12-31 | 5.30% 10-K · filed 2023-02-15 | |||
| 2020-12-31 | 0.10% 10-K · filed 2023-02-15 | |||
| 2019-12-31 | 0.00% 10-K · filed 2022-02-03 | |||
| 2012-12-31 | 0.00% 10-K · filed 2013-02-05 | |||
| 2011-12-31 | 0.00% 10-K · filed 2013-02-05 | |||
| 2010-12-31 | 5.00% 10-K · filed 2013-02-05 | |||
| 2010-09-30 | 21.60% 10-Q · filed 2011-10-28 | 5.20% 10-Q · filed 2011-10-28 | ||
| 2010-06-30 | 0.80% 10-Q · filed 2011-07-26 | 0.80% 10-Q · filed 2011-07-26 | ||
| 2010-03-31 | 0.80% 10-Q · filed 2011-04-21 | |||
| 2009-09-30 | 0.90% 10-Q · filed 2010-10-26 | 1.10% 10-Q · filed 2010-10-26 | ||
| 2009-06-30 | 1.40% 10-Q · filed 2010-07-20 | 1.20% 10-Q · filed 2010-07-20 | ||
| 2008-12-31 | 0.80% 10-K · filed 2011-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |